Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

欧盟人用医药产品委员会 (CHMP)对Celltrion的三种候选生物仿制药——Eydenzelt® (aflibercept)、Stoboclo®和Osenvelt® (denosumab)以及Avtozma® (tocilizumab)给出积极意见 ...

Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

QUASAR试验是一项全球性、双盲、主动对照研究，比较了EYLEA HD与现有EYLEA治疗的疗效和安全性。两组患者在36周时都达到了非劣效的视力提升，EYLEA HD组在不同类型的RVO（包括中央、分支和半视网膜静脉阻塞）中显示出一致的结果。

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Aflibercept, a biosimilar (a biological medicine that's highly similar to another one that has already been approved), ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...